Latanoprost Viatris

Latanoprost, the active ingredient in Latanoprost Viatris, is a prostaglandin analog presented as an ophthalmic solution for ocular administration. It is used to lower intra‑ocular pressure in patients with primary open‑angle glaucoma and ocular hypertension, helping to prevent optic nerve damage and visual field loss.

GNH USA supplies Latanoprost Viatris as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under stringent quality standards. The product conforms to EU regulatory requirements and is manufactured under validated processes to ensure consistency and safety.

Latanoprost is a prostaglandin analog used to manage ocular conditions characterized by elevated intra‑ocular pressure.

- Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent conversion to glaucoma. - Secondary open‑angle glaucoma: decreases pressure in a similar manner.

Latanoprost may cause ocular and systemic adverse reactions, most of which are mild and transient.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eye irritation: burning or stinging sensation. - Increased iris pigmentation: gradual darkening of iris color. - Eyelash changes: lengthening or thickening of eyelashes. - Blurred vision: temporary visual disturbance.

Serious or Rare Side Effects: - Anterior uveitis: inflammation of the anterior uveal tract. - Corneal edema: swelling of the cornea affecting vision. - Severe allergic reaction: swelling, itching, or rash requiring medical attention.

Before initiating therapy, consider the following precautions.

- Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown; consider potential risk to infant. - Contact lens wearers: may cause deposits; remove lenses before instillation. - Concurrent ocular surgery: postpone use until postoperative healing is complete. - Monitor intra‑ocular pressure: ensure adequate response after initiation. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost may interact with other ophthalmic or systemic agents.

Major Interactions (Avoid): - Prostaglandin analogs with other intra‑ocular pressure‑lowering agents: risk of excessive pressure reduction. - Systemic NSAIDs: may diminish prostaglandin effect.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive IOP‑lowering effect; monitor pressure. - Carbonic anhydrase inhibitors: combined therapy may increase efficacy; watch for side effects. - Anticholinergic eye drops: possible reduced efficacy.